LFTD Partners Inc. Reports Q1 2023 Earnings, 31% Revenue Decrease YoY, How About Net Loss?

The corporate parent of Lifted Made, LFTD Partners Inc. (OTCQB: LIFD) reported its Q1 2023 financial results, revealing a 31% revenue decrease and net loss driven by one-time stock compensation expense.

The corporate parent of Lifted Made, LFTD Partners Inc. (OTCQB:LIFD) reported its Q1 2023 financial results, revealing a 31% revenue decrease and net loss driven by one-time stock compensation expense.

Income Statement Highlights: Q1 2023 Compared To Q1 2022

  • Revenue decreased 31% to $12,461,793, down from $18,088,877
  • One-time, non-cash employee stock compensation expense of $2,138,175, up from $0 Net loss of $141,742, down from net income of $2,944,793
  • Basic net loss per common share of $0.01 per share, down from $0.21 basic net income per common share
  • Diluted net loss per common share of $0.01 per share, down from $0.18 diluted net income per common share
  • Basic and diluted weighted average shares outstanding for the three months ended March 31, 2023, were 14,246,745 and 14,246,745, respectively.

Balance Sheet Highlights: March 31, 2023, Compared to December 31, 2022

  • Cash on hand decreased 2% to $3,470,125, down from $3,530,623
  • Inventory increased 26% to $7,563,500, up from $6,023,967
  • Current assets increased 8% to $14,923,190, up from $13,853,949
  • The current ratio increased 17% to 2.61, from 2.23 Working capital increased 20% to $9,210,158, up from $7,643,816
  • No debt as of March 31, 2023

“We’ve made tremendous progress this year to position ourselves for long-term growth and we generated over $12 million in top line and generated over $2 million in EBITDA in Q,” said Nicholas S. Warrender, vice chairman and COO of LFTD Partners and founder and CEO of Lifted Made.

“During the first quarter of 2023, LFTD Partners recognized a net loss after ten straight quarters of profitability, solely because of the impact of a one-time, non-cash employee stock compensation expense of $2.1 million,” said Gerard M. Jacobs, chairman and CEO of LFTD Partners.

Jacobs pointed out that the allocation of deferred stock as compensation to retain employees during the Lifted Made acquisition resulted in a one-time charge that caused the company to shift from a positive net income of $1.4 million to a net loss of $141,000, impacting the reported earnings per share for Q1 2023.

Photo: Courtesy Of Markus Spiske On Unsplash

Total
0
Shares
Related Posts
Read More

Sarepta Therapeutics Announces That U.S. FDA Has Accepted For Filing And Granted Priority Review For The Biologics License Application For SRP-9001, Sarepta’s Gene Therapy For The Treatment Of Ambulant Individuals With Duchenne Muscular Dystrophy

–  Regulatory action date of May 29, 2023 –  SRP-9001 would be the first gene therapy for Duchenne, a one-time treatment designed to treat the underlying cause of DMD by delivering a functional

SRPT